SK1795A3 - Drug delivery device and method of this production - Google Patents

Drug delivery device and method of this production Download PDF

Info

Publication number: SK1795A3
Authority: SK; Slovakia
Prior art keywords: polymer; drug; dosage form; cross; matrix
Prior art date: 1992-07-07

Application number

SK17-95A

Other languages

English (en)

Slovak (sk)

Inventor

Helle Brondsted

Lars Hovgaard

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-07

Filing date

1993-07-06

Publication date

1995-09-13

1993-07-06 Application filed by Astra Ab filed Critical Astra Ab

1995-09-13 Publication of SK1795A3 publication Critical patent/SK1795A3/sk

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 4
238000000034 method Methods 0.000 title claims description 12
238000012377 drug delivery Methods 0.000 title abstract description 4
239000003814 drug Substances 0.000 claims abstract description 70
229940079593 drug Drugs 0.000 claims abstract description 58
239000000017 hydrogel Substances 0.000 claims abstract description 57
239000011159 matrix material Substances 0.000 claims abstract description 38
108010001682 Dextranase Proteins 0.000 claims abstract description 30
229920000642 polymer Polymers 0.000 claims abstract description 22
239000003431 cross linking reagent Substances 0.000 claims abstract description 20
238000004132 cross linking Methods 0.000 claims abstract description 18
229920006237 degradable polymer Polymers 0.000 claims abstract description 18
238000006243 chemical reaction Methods 0.000 claims abstract description 10
239000002904 solvent Substances 0.000 claims abstract description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 29
239000002552 dosage form Substances 0.000 claims description 27
229920002307 Dextran Polymers 0.000 claims description 22
239000000499 gel Substances 0.000 claims description 22
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 16
230000015556 catabolic process Effects 0.000 claims description 15
238000006731 degradation reaction Methods 0.000 claims description 15
230000008961 swelling Effects 0.000 claims description 14
229960000890 hydrocortisone Drugs 0.000 claims description 8
239000005057 Hexamethylene diisocyanate Substances 0.000 claims description 7
229920006395 saturated elastomer Polymers 0.000 claims description 5
239000011541 reaction mixture Substances 0.000 claims description 4
238000013270 controlled release Methods 0.000 claims description 3
RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical group O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 3
ALQLPWJFHRMHIU-UHFFFAOYSA-N 1,4-diisocyanatobenzene Chemical compound O=C=NC1=CC=C(N=C=O)C=C1 ALQLPWJFHRMHIU-UHFFFAOYSA-N 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
239000000178 monomer Substances 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
238000010521 absorption reaction Methods 0.000 claims 1
239000007767 bonding agent Substances 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
210000001072 colon Anatomy 0.000 abstract description 29
229960002086 dextran Drugs 0.000 description 18
239000000203 mixture Substances 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
210000002784 stomach Anatomy 0.000 description 11
210000000813 small intestine Anatomy 0.000 description 10
239000000243 solution Substances 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
150000001768 cations Chemical class 0.000 description 5
150000004676 glycans Chemical class 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000004480 active ingredient Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
229940088679 drug related substance Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
239000008351 acetate buffer Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000011888 foil Substances 0.000 description 3
235000011389 fruit/vegetable juice Nutrition 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 2
229920002567 Chondroitin Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
230000007423 decrease Effects 0.000 description 2
229940119743 dextran 70 Drugs 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000027119 gastric acid secretion Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000008103 glucose Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
108010065511 Amylases Proteins 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000252983 Caecum Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000019399 Colonic disease Diseases 0.000 description 1
229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
229940025131 amylases Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
108010066657 azoreductase Proteins 0.000 description 1
239000012620 biological material Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
-1 hydrogen ions Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000463 material Substances 0.000 description 1
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
229960004963 mesalazine Drugs 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
231100000404 nontoxic agent Toxicity 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Retarders (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK17-95A 1992-07-07 1993-07-06 Drug delivery device and method of this production SK1795A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK92895A DK89592D0 (da)	1992-07-07	1992-07-07	Laegemiddelafgivelsesindretning samt fremgangsmaade til fremstilling deraf
PCT/DK1993/000227 WO1994001136A1 (en)	1992-07-07	1993-07-06	A drug delivery device and a method of making such device

Publications (1)

Publication Number	Publication Date
SK1795A3 true SK1795A3 (en)	1995-09-13

Family

ID=8098759

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK17-95A SK1795A3 (en)	1992-07-07	1993-07-06	Drug delivery device and method of this production

Country Status (15)

Country	Link
EP (1)	EP0648129A1 (cs)
JP (1)	JPH07508735A (cs)
KR (1)	KR950702437A (cs)
AU (1)	AU671651B2 (cs)
BR (1)	BR9306700A (cs)
CA (1)	CA2139747A1 (cs)
CZ (1)	CZ3895A3 (cs)
DK (1)	DK89592D0 (cs)
FI (1)	FI950065A7 (cs)
HU (1)	HUT75665A (cs)
NZ (1)	NZ253678A (cs)
PL (1)	PL172724B1 (cs)
RU (1)	RU2139093C1 (cs)
SK (1)	SK1795A3 (cs)
WO (1)	WO1994001136A1 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5783214A (en) *	1994-06-13	1998-07-21	Buford Biomedical, Inc.	Bio-erodible matrix for the controlled release of medicinals
ES2198579T3 (es) *	1996-07-01	2004-02-01	Universiteit Utrecht	Hidrogeles hidrolizables para liberacion controlada.
CN1402629A (zh)	1999-12-23	2003-03-12	辉瑞产品公司	提供提高的药物浓度的药物组合物
JP2013523748A (ja) *	2010-03-29	2013-06-17	サーモディクス，インコーポレイテッド	注射用薬物送達製剤
JP6199883B2 (ja)	2011-12-05	2017-09-20	インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ	医療用オルガノゲルプロセス及び組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2550750A (en) *	1947-09-22	1951-05-01	Arthur C Abelt	Differential for automobiles
US4024073A (en) *	1972-01-08	1977-05-17	Toray Industries, Inc.	Hydrogel and production thereof
JPS57500432A (cs) *	1980-03-20	1982-03-11
IT1131833B (it) *	1980-06-20	1986-06-25	Crinos Industria Farmaco	Eccipienti per sostanze spermicide
JPS5997346A (ja) *	1982-11-24	1984-06-05	Komatsu Ltd	車両のデイフアレンシヤル装置
US4925677A (en) *	1988-08-31	1990-05-15	Theratech, Inc.	Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
SE9002339L (sv) *	1990-07-04	1992-01-05	Kabi Pharmacia Ab	Terapeutisk komposition och foerfarande foer dess framstaellning

1992
- 1992-07-07 DK DK92895A patent/DK89592D0/da not_active Application Discontinuation
1993
- 1993-07-06 CA CA002139747A patent/CA2139747A1/en not_active Abandoned
- 1993-07-06 EP EP93914649A patent/EP0648129A1/en not_active Withdrawn
- 1993-07-06 WO PCT/DK1993/000227 patent/WO1994001136A1/en not_active Ceased
- 1993-07-06 AU AU44178/93A patent/AU671651B2/en not_active Ceased
- 1993-07-06 HU HU9500042A patent/HUT75665A/hu unknown
- 1993-07-06 CZ CZ9538A patent/CZ3895A3/cs unknown
- 1993-07-06 NZ NZ253678A patent/NZ253678A/en unknown
- 1993-07-06 PL PL93307050A patent/PL172724B1/pl unknown
- 1993-07-06 JP JP6502843A patent/JPH07508735A/ja not_active Expired - Lifetime
- 1993-07-06 SK SK17-95A patent/SK1795A3/sk unknown
- 1993-07-06 RU RU95105519A patent/RU2139093C1/ru active
- 1993-07-06 BR BR9306700A patent/BR9306700A/pt not_active Application Discontinuation
- 1993-07-06 KR KR1019950700048A patent/KR950702437A/ko not_active Ceased
1995
- 1995-01-05 FI FI950065A patent/FI950065A7/fi unknown

Also Published As

Publication number	Publication date
PL307050A1 (en)	1995-05-02
DK89592D0 (da)	1992-07-07
PL172724B1 (pl)	1997-11-28
FI950065A0 (fi)	1995-01-05
HUT75665A (en)	1997-05-28
FI950065A7 (fi)	1995-03-02
WO1994001136A1 (en)	1994-01-20
NZ253678A (en)	1996-07-26
JPH07508735A (ja)	1995-09-28
BR9306700A (pt)	1998-12-08
CA2139747A1 (en)	1994-01-20
EP0648129A1 (en)	1995-04-19
HU9500042D0 (en)	1995-03-28
CZ3895A3 (en)	1995-09-13
KR950702437A (ko)	1995-07-29
AU4417893A (en)	1994-01-31
AU671651B2 (en)	1996-09-05
RU2139093C1 (ru)	1999-10-10

Publication	Publication Date	Title
RU2093148C1 (ru)	1997-10-20	Композиции с замедленным (пролонгированным) высвобождением
US6284273B1 (en)	2001-09-04	Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
Dixit et al.	2013	Sustained release drug delivery system
Kamel et al.	2008	Pharmaceutical significance of cellulose: A review
Kashyap et al.	2005	Hydrogels for pharmaceutical and biomedical applications
KR0157280B1 (ko)	1998-11-16	하부소화관 방출성의 경구의약제제
Khiste et al.	2021	A Review on Applications of Hydroxy Propyl Methyl Cellulose and Natural polymers for the development of modified release drug delivery systems
JPH05502894A (ja)	1993-05-20	放出制御性製剤及び方法
JPH08502036A (ja)	1996-03-05	酵素的に制御された薬剤放出のための架橋されたポリヒドロキシ材料
JP2821952B2 (ja)	1998-11-05	下部消化管放出性の経口医薬製剤
SK1795A3 (en)	1995-09-13	Drug delivery device and method of this production
EP3846784B1 (en)	2026-04-22	Controlled drug release formulation
US20230181479A1 (en)	2023-06-15	Polymer based formulation for release of drugs and bioactives at specific git sites
JP2638604B2 (ja)	1997-08-06	徐放性製剤
EP2446877A1 (en)	2012-05-02	Modified starch derivative-based matrix for colon targeting
WO1997029777A1 (en)	1997-08-21	Drug delivery system using galactoxyloglucan
JPH0130A (ja)	1989-01-05	徐放性製剤
Tangde et al.	2021	Sustained release matrix type drug delivery systems; a review
KR100212432B1 (ko)	1999-08-02	대장 약물전달 조성물
Kumar et al.	2025	Matrix formers
Sharma et al.	2017	Various Approaches Used For Colonic Drug Delivery System
Garapati et al.	2015	Tailoring the Release of Drugs Using Excipients